|
Immunotherapy
Citations 261-270 of 577 total displayed.
|
Past content
(since Jun 2000):
|
Antigen-induced regulatory T cells
- Stephane Vigouroux, Eric Yvon, Ettore Biagi, and Malcolm K. Brenner
Blood 2004; 104: 26-33.
[Abstract]
[Full text]
[PDF]
Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells
- Takehito Igarashi, Jason Wynberg, Ramprasad Srinivasan, Brian Becknell, J. Phillip McCoy, Jr, Yoshiyuki Takahashi, Dante A. Suffredini, W. Marston Linehan, Michael A. Caligiuri, and Richard W. Childs
Blood 2004; 104: 170-177.
[Abstract]
[Full text]
[PDF]
An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line
- Maria-Ana Ghetie, Radu Marches, Stephanie Kufert, and Ellen S. Vitetta
Blood 2004; 104: 178-183.
[Abstract]
[Full text]
[PDF]
Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells
- Claudia Palena, MingZhu Zhu, Jeffrey Schlom, and Kwong-Yok Tsang
Blood 2004; 104: 192-199.
[Abstract]
[Full text]
[PDF]
Identification of an HLA-A*0201–restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein
- Baomei Wang, Huabiao Chen, Xiaodong Jiang, Minghui Zhang, Tao Wan, Nan Li, Xiangyang Zhou, Yanfeng Wu, Feng Yang, Yizhi Yu, Xiaoning Wang, Ruifu Yang, and Xuetao Cao
Blood 2004; 104: 200-206.
[Abstract]
[Full text]
[PDF]
Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen–specific cytotoxic T lymphocytes
- Liesbeth E. M. Oosten, Els Blokland, Astrid G. S. van Halteren, Julie Curtsinger, Matthew F. Mescher, J. H. Frederik Falkenburg, Tuna Mutis, and Els Goulmy
Blood 2004; 104: 224-226.
[Abstract]
[Full text]
[PDF]
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
- Andres Forero, Paul L. Weiden, Julie M. Vose, Susan J. Knox, Albert F. LoBuglio, Jordan Hankins, Michael L. Goris, Vincent J. Picozzi, Don B. Axworthy, Hazel B. Breitz, Robert B. Sims, Richard G. Ghalie, Sui Shen, and Ruby F. Meredith
Blood 2004; 104: 227-236.
[Abstract]
[Full text]
[PDF]
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
- Michele Ghielmini, Shu-Fang Hsu Schmitz, Sergio B. Cogliatti, Gabriella Pichert, Jörg Hummerjohann, Ursula Waltzer, Martin F. Fey, Daniel C. Betticher, Giovanni Martinelli, Fedro Peccatori, Urs Hess, Emanuele Zucca, Roger Stupp, Tibor Kovacsovics, Claudine Helg, Andreas Lohri, Mario Bargetzi, Daniel Vorobiof, and Thomas Cerny
Blood 2004; 103: 4416-4423.
[Abstract]
[Full text]
[PDF]
Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia
- Roberto Stasi, Maurizio Brunetti, Elisa Stipa, and Sergio Amadori
Blood 2004; 103: 4424-4428.
[Abstract]
[Full text]
[PDF]
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study
- Leo I. Gordon, Arturo Molina, Thomas Witzig, Christos Emmanouilides, Andrew Raubtischek, Mohamed Darif, Russell J. Schilder, Greg Wiseman, and Christine A. White
Blood 2004; 103: 4429-4431.
[Abstract]
[Full text]
[PDF]
|
|
